Fate Therapeutics (FATE) Capital Expenditures (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Capital Expenditures data on file, last reported at $239000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 63.51% year-over-year to $239000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 608.96% YoY) and the FY2025 annual result came in at $6.0 million, up 4152.14% from the prior year.
• Capital Expenditures slipped to $239000.0 in Q1 2026, from $5.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $16.8 million in Q2 2022 to a low of -$27.8 million in Q4 2022.
• A 5-year average of $796470.6 and a median of $338000.0 in 2025 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 4578.57% in 2025, down 391.74% in 2025.
• Tracing FATE's Capital Expenditures over 5 years: stood at -$27.8 million in 2022, then soared by 121.5% to $6.0 million in 2023, then slumped by 97.93% to $124000.0 in 2024, then soared by 4379.84% to $5.6 million in 2025, then slumped by 95.7% to $239000.0 in 2026.
• The last three Capital Expenditures figures came in at $239000.0 (Q1 2026), $5.6 million (Q4 2025), and -$595000.0 (Q3 2025), per Business Quant data.